insights_auto
Kwa nini CRSP imeongezeka kwa 5.85%?
Fahamu zaidichevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
US$ 53.39
arrow_upward
+5.85%(+2.95) Siku 1
US$ 54.10
arrow_upward
+1.33% (+0.71)bedtimeBaada ya saa
Imefungwa: 9 Okt, 16:00:00 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya CRSP...
Fungua
US$ 50.82
Juu
US$ 54.07
Chini
US$ 50.52
Mtaji wa soko
5.16B
Wastani wa kiasi cha mauzo
1.62M
Kiasi cha mauzo ya hisa
1.47M
Juu kwa wiki 52
US$ 78.00
Chini kwa wiki 52
US$ 44.12
EPS
-US$ 4.76
Beta
1.45
Hisa za wawekezaji
96.69M
Idadi ya wafanyakazi
393
Fungua
US$ 50.82
Juu
US$ 54.07
Chini
US$ 50.52
Mtaji wa soko
5.16B
Wastani wa kiasi cha mauzo
1.62M
Kiasi cha mauzo ya hisa
1.47M
Juu kwa wiki 52
US$ 78.00
Chini kwa wiki 52
US$ 44.12
EPS
-US$ 4.76
Beta
1.45
Hisa za wawekezaji
96.69M
Idadi ya wafanyakazi
393
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Simply Wall Street
·
saa 15 zilizopita
Upcoming CTX310 Data Could Test The Case For CRISPR Therapeutics Stock
Investing.com
·
saa 15 zilizopita
Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics
MarketBeat
·
saa 23 zilizopita
CRISPR Therapeutics (NASDAQ:CRSP) Shares Climb 5.7% - What's Next?
The Motley Fool
·
siku 1 iliyopita
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Wasifu
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Kuhusu Crispr Therapeutics AG
Afisa Mkuu Mtendaji (CEO)Samarth Kulkarni
Wafanyakazi393
Lilianzishwa2013
Makao makuuZug, Jimbo la Zug, Uswisi
Sekta-
Tovuticrisprtx.com